Thermo Fisher Scientific Inc.
TMO
$492.60
$3.110.64%
NYSE
| 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.21B | 42.90B | 42.88B | 42.37B | 42.35B |
| Total Other Revenue | 1.00M | -- | -- | -- | -- |
| Total Revenue | 43.21B | 42.90B | 42.88B | 42.37B | 42.35B |
| Cost of Revenue | 25.37B | 25.12B | 25.13B | 25.05B | 25.03B |
| Gross Profit | 17.84B | 17.77B | 17.75B | 17.32B | 17.31B |
| SG&A Expenses | 8.45B | 8.50B | 8.60B | 8.51B | 8.47B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 30.00M | 30.00M | 30.00M | 1.00M | 1.00M |
| Total Operating Expenses | 35.26B | 35.05B | 35.15B | 34.91B | 34.82B |
| Operating Income | 7.95B | 7.85B | 7.73B | 7.46B | 7.53B |
| Income Before Tax | 7.02B | 6.99B | 7.00B | 6.76B | 6.78B |
| Income Tax Expenses | 436.00M | 472.00M | 658.00M | 641.00M | 595.00M |
| Earnings from Continuing Operations | 6.58K | 6.52K | 6.34K | 6.12K | 6.19K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -4.00M | -4.00M | 14.00M | 34.00M |
| Net Income | 6.58B | 6.52B | 6.34B | 6.14B | 6.22B |
| EBIT | 7.95B | 7.85B | 7.73B | 7.46B | 7.53B |
| EBITDA | 10.82B | 10.83B | 10.84B | 10.66B | 10.84B |
| EPS Basic | 17.32 | 17.10 | 16.59 | 16.01 | 16.18 |
| Normalized Basic EPS | 12.43 | 12.18 | 12.05 | 11.53 | 11.62 |
| EPS Diluted | 17.29 | 17.05 | 16.53 | 15.95 | 16.12 |
| Normalized Diluted EPS | 12.40 | 12.14 | 12.00 | 11.49 | 11.58 |
| Average Basic Shares Outstanding | 1.52B | 1.52B | 1.53B | 1.53B | 1.54B |
| Average Diluted Shares Outstanding | 1.52B | 1.53B | 1.53B | 1.54B | 1.54B |
| Dividend Per Share | 1.64 | 1.60 | 1.56 | 1.52 | 1.48 |
| Payout Ratio | 9.26% | 9.16% | 9.20% | 9.29% | 8.92% |